Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson’s disease induced by MPTP

[1]  Zhiqiang Zhang,et al.  Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF‐&kgr;B signaling pathway in a mouse model of Parkinson's disease , 2019, Life sciences.

[2]  W. Teo,et al.  Parkinson's Disease and the Environment , 2019, Front. Neurol..

[3]  Junxia Xie,et al.  Rosmarinic acid protects against MPTP-induced toxicity and inhibits iron-induced α-synuclein aggregation , 2019, Neuropharmacology.

[4]  Alberto Priori,et al.  Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? , 2018, Journal of Neural Transmission.

[5]  Xiansi Zeng,et al.  Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment , 2018, ASN neuro.

[6]  Rita G. W. Pires,et al.  Behavioral, Biochemical and Molecular Characterization of a Parkinson’s Disease Mouse Model Using the Neurotoxin 2′-CH3-MPTP: A Novel Approach , 2018, NeuroMolecular Medicine.

[7]  J. Obeso,et al.  Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification , 2017, Experimental Neurology.

[8]  N. Chen,et al.  Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease , 2017, Acta Pharmacologica Sinica.

[9]  K. Chaudhuri,et al.  Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.

[10]  Vyoma D. Shah,et al.  Aging Affects Dopaminergic Neural Mechanisms of Cognitive Flexibility , 2016, The Journal of Neuroscience.

[11]  L. B. Areal,et al.  Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson’s Disease , 2016, Journal of Molecular Neuroscience.

[12]  M. Biavatti,et al.  Rosmarinic Acid – Pharmaceutical and Clinical Aspects , 2016, Planta Medica.

[13]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[14]  C. Bishop,et al.  Modulation of l-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus , 2015, Neuropharmacology.

[15]  Marc Flajolet,et al.  Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems , 2013, Trends in Neurosciences.

[16]  Junxia Xie,et al.  Neurorescue Effect of Rosmarinic Acid on 6-Hydroxydopamine-Lesioned Nigral Dopamine Neurons in Rat Model of Parkinson's Disease , 2012, Journal of Molecular Neuroscience.

[17]  Regina Katzenschlager,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[18]  Junxia Xie,et al.  Rosmarinic Acid Antagonized 1-Methyl-4-Phenylpyridinium (MPP+)-Induced Neurotoxicity in MES23.5 Dopaminergic Cells , 2010, International journal of toxicology.

[19]  Cai Song,et al.  Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease , 2009, Physiology & Behavior.

[20]  Junxia Xie,et al.  Rosmarinic Acid Inhibits 6-OHDA-induced Neurotoxicity by Anti-oxidation in MES23.5 Cells , 2009, Journal of Molecular Neuroscience.

[21]  J. Beard,et al.  Iron deficiency alters dopamine uptake and response to L‐DOPA injection in Sprague–Dawley rats , 2008, Journal of neurochemistry.

[22]  G. Miller,et al.  Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice , 2007, Proceedings of the National Academy of Sciences.

[23]  K. Rommelfanger,et al.  Norepinephrine: The redheaded stepchild of Parkinson's disease. , 2007, Biochemical pharmacology.

[24]  M. Mattson,et al.  Ageing and neuronal vulnerability , 2006, Nature Reviews Neuroscience.

[25]  M. Vila,et al.  MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease , 2004, Journal of bioenergetics and biomembranes.

[26]  L. Tremblay,et al.  Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice , 2003, Neurobiology of Disease.

[27]  N. P. Kedar.  Can we prevent Parkinson's and Alzheimer's disease? , 2003, Journal of postgraduate medicine.

[28]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[29]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[30]  S. Y. Wang,et al.  Antioxidant activity and phenolic compounds in selected herbs. , 2001, Journal of agricultural and food chemistry.

[31]  Y. Agid,et al.  Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[32]  T. Slotkin.  Mary Bernheim and the discovery of monoamine oxidase , 1999, Brain Research Bulletin.

[33]  J. Brotchie,et al.  The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease , 1999 .

[34]  M. Franklin,et al.  Simultaneous determination of catecholamines in rat brain tissue by high-performance liquid chromatography. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[35]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[36]  E. Bézard,et al.  Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach , 1998, Progress in Neurobiology.

[37]  N. Ogawa,et al.  Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion , 1997, Journal of Neuroscience Methods.

[38]  G. Rozas,et al.  Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test , 1997, Brain Research.

[39]  K. Jellinger,et al.  The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.

[40]  K. Jellinger,et al.  Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.

[41]  G. M. Halliday,et al.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease , 1990, Brain Research.

[42]  W. Gibb.  Neuropathology in movement disorders. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[43]  H. Tilson,et al.  Assessment of chemically-induced changes in the neuromuscular function of rats using a new recording grip meter. , 1978, Life sciences.

[44]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[45]  N W DUNHAM,et al.  A note on a simple apparatus for detecting neurological deficit in rats and mice. , 1957, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[46]  A. Wahi,et al.  ANTIOXIDANTS AS IMMUNOMODULATOR: AN EXPANDING RESEARCH AVENUE , 2011 .

[47]  M. Simmonds,et al.  Rosmarinic acid. , 2003, Phytochemistry.

[48]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.